CClinicalTrials.gg
Status unknownNCT00977002Updated Feb 2, 2011

Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation

A Phase 3 interventional study of Positive Pressure Noninvasive ventilation and Inhalatory O2 in Extubation Failure and Acute Respiratory Failure Post Extubation, sponsored by UPECLIN HC FM Botucatu Unesp. Status unknown at 1 site in Brazil. Open to participants aged 28 Days to 15 Years. Per ClinicalTrials.gov, last updated 2011-02-02.

Sponsored by UPECLIN HC FM Botucatu Unesp · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2011), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
28 Days to 15 Years
Sex
All
01

Study summary

Child extubation failure range from 4.1% to 19%. Studies in adults and children showed that extubation failure increases mortality mainly in those who need reintubation as this is a invasive procedure associated with many complications. Therefore, patients are reintubated when they worsen, which can contribute to organ dysfunction and increased mortality.

Positive Pressure Noninvasive ventilation (PPNIV) has been proposed as a way to treat acute respiratory distress, avoiding complications of intubation and invasive ventilation. Most of the studies in adults are not conclusive on the benefits of PPNIV as a way to treat post-extubation acute respiratory distress. However, studies that evaluated the early use of PPNIV in post-extubation period as a way to prevent respiratory failure tend to show some advantages as decrease of reintubation, decrease number of respiratory distress, decrease of hospital infection frequency and lower mortality rate in the intensive care unit (ICU) for those who use PPNIV.

In a prospective study on the use of PPNIV in 114 children, Essouri at al avoided invasive ventilation in 77%, being the group in patients with post-extubation respiratory distress.

As far as the investigators know there is not any randomized, controlled study in children examining the PPNIV as a way to prevent post-extubation respiratory distress. The investigators' hypothesis is that PPNIV decreases the extubation failure rate and, as a consequence, the Pediatric Intensive Care Unit (PICU) and hospital length of stay, and mortality rate.

The objective is to compare PPNIV and inhalatory O2 (catheter or facial mask) in children after extubation, evaluating the need of reintubation, hospital and PICU mortality rate and length of stay in PICU and hospital.

Read the detailed description

Prospective, randomized and controlled study at the PICU - University Hospital, Botucatu Medical School-UNESP. Patients elegibled are exposed to extubation test. If passed they are randomized in two groups: 1) post-extubation PPNIV (PPNIV, n=50), and 2) Inhalatory oxygen therapy by nasal catheter or facial mask (O2I, n=50). Patients are observed for 48 hours, being considered extubation failure if they need reintubation. Arterial blood gas is obtained at the day or programed extubation and one hour after extubation.

Nasal prongs and facial or nasal masks are used in accordance with child age. All patients from this group are kept in PPNIV for a 12 hours at least. Feeding, if released, is done by gastric probe.

In O2IG, patients use facial mask or nasal catheter after extubation. Both groups are submitted to physiotherapy and nurse care as the PICU routine Follow up: Variables: age, gender, disease and comorbidities, intubation cause , time intubated and invasive ventilation use, PRISM score at the moment of admission, risk factors to respiratory distress post extubation, Comfort scale just before extubation, use of sedatives (time and mean dose)during invasive ventilation. At randomization and one hour later: vital signs, arterial blood gas. Patients are followed for 48 hour to evaluate reintubation and then for other complications, death and length of stay in PICU and hospital.

02

Conditions studied

  • Extubation Failure
  • Acute Respiratory Failure Post Extubation

Keywords

  • noninvasive ventilation
  • extubation
  • Respiratory failure
  • reintubation
03

In context

Respiratory Insufficiency

1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.

This study's planned enrollment of 100 is above the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

UPECLIN HC FM Botucatu Unesp is the lead sponsor of 63 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Patients aged between 28 days and 15 years and who were intubated and remained under invasive mechanical ventilation for 48 hours, passed in the extubation test for, and who presented at least one of the following risk factors for respiratory distress post extubation:

  1. Invasive ventilation for at least 15 days
  2. Use of inotropics for more than 48 hours
  3. Endovenous continuous administration of sedative/analgesic drugs
  4. 1-3 months old
  5. Mean Airway Pressure(Paw)> 8,5; Inspired fraction of O2(FiO2)> 0,4; Oxygenation index(IO)> 4,5 immediately before extubation
  6. Cardiac or pulmonary chronic diseases
  7. Cardiac output
  8. Hipercapny: Arterial pressure of CO2 (PaCO2)> 45 mmHg

Exclusion criteria

Exclusion Criteria:

  1. Tracheostomized
  2. Accidental extubation
  3. Respiratory failure just after extubation, needing immediate reintubation
  4. Neuromuscular diseases
  5. Death
  6. PPNIV exclusion: coma or disability to protect airway, not tolerated, hemodynamic instability, shock, cardiac disritmy, facial or intracranial traumatic injury or surgery that preclude use of mask, abdominal distension, nausea or vomiting, gastric or esophagic recent surgery, gastrointestinal hemorrhagy in activity, not drained pneumothorax.
  7. Reintubated patients during its stay in PICU, that have already participated in this study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    PPNIV

    Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation

    Other: Positive Pressure Noninvasive ventilation

  • Active comparator
    O2I

    Patient randomized to this group will be submitted to traditional oxygen therapy post extubation

    Other: Inhalatory O2

Interventions

  • OtherPositive Pressure Noninvasive ventilation

    Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.

    Also known as: Noninvasive ventilation

  • OtherInhalatory O2

    Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.

    Also known as: Oxygen therapy

06

What researchers measure

Primary outcomes

  1. Prevention of reintubation

    Time frame: 48 hours

Secondary outcomes

  1. decrease of PICU and hospital mortality

    Time frame: 28 days

  2. decrease of hospital and PICU length of stay

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
  • Botucatu Medical School-UNESP
    Botucatu, Sao Paulo 18.618-970, Brazil
    • Rafaelle F Batistella, MD · Contact · rafaellefb@yahoo.com.br · +55-1438116300
    • José R Fioretto, MD, PhD · Contact · jrf@fmb.unesp.br · +55-1438116274
    • Rafaelle F Batistella, MD · Principal investigator
    • José R Fioretto, PhD · Sub investigator
    • Mário F Carpi, PhD · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00977002
Lead sponsor
UPECLIN HC FM Botucatu Unesp
First posted
Sep 15, 2009
Start date
Mar 2008
Primary completion
Dec 2009 (estimated)
Completion
Dec 2010 (estimated)
Last update
Feb 2, 2011

Study contacts

Rafaelle F Batistella, MD
Contact
rafaellefb@yahoo.com.br
+55-1438116300
José R Fioretto, MD, PhD
Contact
jrf@fmb.unesp.br
+55-1438116274
Rafaelle F Batistella
principal investigator · FMB - UNESP
José R Fioretto
study director · FMB-UNESP
Mário F Carpi
study chair · FMB-UNESP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion